Transgene

Transgene Pre-Tax Margin

The Pre-Tax Profit Margin of Transgene (TNG.PA) as of Nov 18, 2026 is -558.64 %. In the previous year, Pre-Tax Profit Margin was -292.48 % — a change of 91.00% (lower).

Pre-Tax Margin

-558.64 %

YoY

91.00%

Last updated:

Pre-Tax Profit Margin of Transgene is 2024 -558.64 % . Pre-Tax Profit Margin of Transgene was 2023 -292.48 % . It decreases by 91.00% lower compared to the previous year.

The Transgene Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2017
-432.80 EUR
Jan 1, 2018
113.30 EUR
Jan 1, 2019
-141.43 EUR
Jan 1, 2020
-184.43 EUR
Jan 1, 2021
-114.82 EUR
Jan 1, 2022
-327.97 EUR
Jan 1, 2023
-292.48 EUR
Jan 1, 2024
-558.64 EUR
The Transgene Pre-Tax Margin history
YEARPre-Tax MarginYoY
-558.64 %+91.00%
-292.48 %-10.82%
-327.97 %+185.63%
-114.82 %-37.74%
-184.43 %+30.41%
-141.43 %-224.83%
113.30 %-126.18%
-432.80 %+56.20%
-277.07 %-30.09%
-396.33 %+6.99%
-370.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Pre-Tax Profit Margin of Transgene is -558.64 % in 2024.

Pre-Tax Profit Margin of Transgene changed from -292.48 % to -558.64 %, representing a 91.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Transgene since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Transgene

All Key Metrics — Transgene